A biopharmaceutical company leveraging our innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Our VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which we believe will induce broad, robust, and durable protection against the specific viruses targeted.
Lead Underwriter
Cowen and Company, LLC, Evercore Group L.L.C, Jefferies LLC, William Blair & Company, L.L.C.
